Takahiro Niimura
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Gendered innovation in cancer chemotherapy - real world data driven pharmacological research
Open Date: 2022-04-01
Close Date: 2025-03-31
Grant: Close
大規模医療情報を用いた薬剤性心筋炎治療薬の探索および有効性の検証
Open Date: 2022-04-01
Close Date: 2025-03-31
Grant: Close
医療ビッグデータおよびオミクスデータを活用した薬剤性心筋炎に対する治療法の開発
Open Date: 2021-08-30
Close Date: 2023-03-31
Grant: Close
Elucidation of the relationship between infectious diseases and aortic diseases by big data analysis and in vivo experiments
Open Date: 2021-04-01
Close Date: 2024-03-31
Grant: Close
ドラッグリポジショニング手法を用いた新規心肺蘇生後脳症治療薬の探索
Open Date: 2019-04-25
Close Date: 2021-03-31
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Aim The concomitant use of lamotrigine and valproic acid, a uridine diphosphate (UDP)‐glucuronosyltransferase inhibitor, is a known risk factor for lamotrigine‐induced rashes, which may develop into fatal or severe cutaneous adverse reactions. No drugs other than valproic acid have been shown to increase lamotrigine concentrations in humans by inhibiting UDP‐glucuronosyltransferase. The treatment of bipolar disorder and epilepsy is often combined with other medications, which may affect the risk of rash. We aimed to identify medications that increased the risk of lamotrigine‐induced rashes using clinical data. Methods We used VigiBase to search for drugs associated with the increased number of reported severe cutaneous adverse reactions when combined with lamotrigine. In a retrospective study, we collected information on patients from electronic medical records and used propensity score matching to compare the incidence of lamotrigine‐induced rash with and without flunitrazepam use. Furthermore, we compared lamotrigine concentrations between patients treated with and without flunitrazepam in a prospective observational study. Results VigiBase analysis showed that flunitrazepam significantly increased the reporting odds ratio for lamotrigine‐related severe cutaneous adverse reactions. In the retrospective study, combining lamotrigine with flunitrazepam significantly increased the incidence of rashes. In the prospective observational study, lamotrigine with flunitrazepam significantly increased the concentration‐to‐dose ratio. Conclusion Flunitrazepam use may affect lamotrigine concentration and increase the risk of rash. These results have implications for the choice of sleep medication. In addition, when lamotrigine is used in combination with flunitrazepam, the lamotrigine dosing design should address lamotrigine‐induced rash management.
Year:
2025
Year:
2025
Interstitial lung disease (ILD) is a clinically relevant adverse event associated with biologic agent use. However, the current incidence of ILD remains unclear as large‐scale risk assessments of biologic agents have not been conducted. The aim of this study was to clarify the association between biologic agent use and ILD development in clinical practice by detecting adverse event signals using a spontaneous adverse drug reaction database. The VigiBase database is used for spontaneous adverse event reporting. The analysis focused on nine biologics used to treat psoriasis, rheumatoid arthritis, and Crohn's disease. The safety of each biologic agent was evaluated using the information component signal detection method. There were 32,520,983 reports in VigiBase, of which 68,489 (0.21%) were for ILD. Signals were mainly detected for tumor necrosis factor‐α inhibitors when the information component for ILD caused by biologic agents was calculated. Comorbidity analysis in patients who developed ILD and analysis of the time from the start of treatment with each drug to ILD onset showed differences for each biologic agent. ILD is a serious adverse effect of biologic agents, and there are several cases in which a causal relationship with ILD development cannot be ruled out. The occurrence of interstitial ILD should be noted when using biologics, particularly TNF‐α inhibitors.
Year:
2025
Chemotherapy‐induced peripheral neuropathy, including oxaliplatin‐induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large‐scale investigations have been conducted in real‐world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin‐containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade ≥ 2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non‐statin groups, even after propensity score matching. However, among the matched patients with CRC ( n = 510), statin use was associated with a significantly lower incidence of Grade ≥ 2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p = 0.029). Our findings indicate that statins may protect against OIPN in patients with CRC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (10)
Keita Hirai
Professor
Wakayama Medical University
Motohiro Okada
Hirosaki University
Koji Yahara
Group Leader
National Institute of Infectious Diseases
Naoya Kamiyama
Asahikawa Medical University
HIDEKI NAWA
Shujitsu University
Tsukasa Higashionna
Okayama Daigaku Daigakuin Ishiyakugaku Sogo Kenkyuka Igakubu
Yusuke Minato
Associate Professor
Fujita Health University
Masahito Nakataki
Tokushima University
Masato Suzuki
National Institute of Infectious Diseases
Satoshi Nakano
Visitting Researcher
Nagoya University
Make your next move.
Prepare your application
Review drafts before you send them.